



Elsa Musini

Contact information	<ul style="list-style-type: none">• Av Medrano 134 Floor 6 Caba. Bs As. Argentina. Zip Codel C1179AAB.• Phone. 054 011 4983 1589.• Email: elsamusini@imoba.com.ar
Education	<ul style="list-style-type: none">• Good clinical practices Quintiles. 2012• Provision 6677/10 ANMAT, Novo Nordisk 2015• Good Clinical Practice Brookwood International Academy, 2015• IATA Mayo Clinic standards, last update 2019• Good clinical practices, Eli Lilly Jun 2017. (last current update)• Data systems for research: Medidata, Inform, Rave, Oracle.• Good Clinical Practice, The Global Health Network, Oct 2021.• IATA Clinica Mayo, Oct 2021.• Diploma in Good Practices in Biomedical Research. University of San Pablo.Tucumán. August 2020 to July 2021 (238 hours).
Current employment information	<ul style="list-style-type: none">• Investigaciones Médicas IMOBA SRL• Av Medrano 134 floor 6 CABA• Study coordinator from 2008 to present.
Clinical studies in the last 5 years	<ul style="list-style-type: none">➤ GSK716155 HARMONY: Long-term, randomized, double-blind, placebo-controlled study to determine the effect of biglutide in addition to standard blood glucose-lowering therapies on major cardiovascular events in patients

with type 2 diabetes. Study coordinator clinical From 2016 to 2018. Phase III. Glaxo

- CLCZ696D2301: Multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of CLCZ696 compared with valsartan, on morbidity and mortality in patients with heart failure (NYHA class II-IV) with preserved ejection fraction. Coordinator of clinical studies, phase III, From 2016 to 2018, Novartis.
- EFC13957: 6-month, multicenter, randomized, open-label, 2-arm, parallel-group study comparing the efficacy and safety of a new formulation of insulin glargine and Lantus injected once daily in children and adolescents aged 6 to 17 years of age with Type 1 Diabetes Mellitus with a 6-month safety extension period. Coordinator of clinical studies. From July 2016 to 2018. Phase III. Sanofi.
- — I8B-MC-ITRN Prospective, double-blind, randomized study of LY900014 compared with insulin Lispro in combination with insulin Glargine or insulin Degludec in adults with type 2 diabetes PRONTO-T2D. From 2016 to 2019. Phase III. Eli Lilly. Studies coordinator.
- I8B-MC-ITRM Prospective, double-blind, randomized study of LY900014 compared with Lispro insulin with an open-label treatment group with postprandial LY900014 in combination with insulin Glargine or insulin Degludec in adults with type 1 diabetes PRONTO-T1D. From 2016 to 2019. Phase III. Eli Lilly. Studies coordinator.
- CLCZ696B2320 Multicenter, randomized, double-blind, parallel-group, active-controlled study to evaluate the effects of LCZ696 compared to VALSARTAN on cognitive function in patients with chronic heart failure and preserved ejection fraction Phase 3. Novartis. Studies coordinator.
- LIK066 Multicenter, randomized, double-blind, parallel-group, dose-finding study to evaluate the effect of 3 doses of LIK066 compared to placebo or pagliflozin in patients with type 2 diabetes mellitus with heart failure. From 2016 to 2018. Phase III. Novartis. Studies coordinator.
- EFC14828 –AMPLITUDE-O - Multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of epeglenatide on cardiovascular outcomes in patients with type 2 diabetes who are at high risk for cardiovascular disease. Sanofi Aventis. Phase III. Study coordinator. From 2017 to Jun 2021.
- EFC14875- SCORED: Multicenter, randomized, double-blind, placebo-controlled study in parallel groups, to demonstrate the effects of zotagliptozin on cardiovascular and renal events in patients with type II diabetes, cardiovascular risk factors and moderate renal failure. Phase III. Sanofi Aventis. From 2017 to April 2021. Studies coordinator.
- Protocol H9X-MC-GBGL "A randomized, double-blind, parallel-arm study to study the efficacy and safety of investigational doses of Dulaglutide when

added to Metformin in patients with type 2 diabetes mellitus." From 2018 to December 2019. Phase III. Coordinator of clinical studies. Eli Lilly.

- 1002-043 (CLEAR), entitled "Randomized, double-blind, placebo-controlled study to evaluate the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with cardiovascular disease or at high risk of developing it, they do not tolerate statins". Phase III. Clixar. Coordinator of clinical studies. From 2018 to the present.
- — K-877-302 Prominent Pemafibrate to reduce cardiovascular outcomes by lowering triglycerides in patients with diabetes. From 2017 to the present. Phase III. Quintiles. Studies coordinator.
- I8F-MC-GPGM Efficacy and safety of Ly3298176 once a week vs insulin glargine in patients with type 2 diabetes and high cardiovascular risk. From March 2018 to July 2021. Phase III. Eli Lilly. Study coordinator.
- I8F-MC-GPGH: Phase 3 open-label, randomized study comparing the effect of LY3298176 vs titrated insulin Degludec on the glycemic control of pts. with type 2 diabetes. Eli Lilly. From July 2018 to April 2021. Phase III. Eli Lilly. Study coordinator.
- I8F-MC-GPGL: Randomized, open-label, phase 3 trial, comparing the efficiency and safety of Tirzepatide vs Semaglutide once a week as an add-on therapy to metformin in patients with type 2 DBT. Eli Lilly. From July 2019 to May 2021. Phase III. Eli Lilly. Study coordinator.
- FINEART s-HF-(Bayer) Multicenter, randomized, double-blind, placebo-controlled parallel group study to evaluate the efficacy and safety of finerenone in morbidity and mortality in patients with Heart Failure (NYHA II-IV) and fraction left ventricular ejection $\geq 40\%$ (LVEF $\geq 40\%$). Phase 3. Study Coordinator. From Oct 2020 to present.
- I8H-MC-BDCL A Phase 2 parallel, comparator- Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin- Native with Type 2 Diabetes Mellitus. Eli Lilly. Study coordinator. From Nov 2020 to present.
- I8F-MC-GPHM Efficacy and SAfefty of Tirzepatide Once Weekly vs Placebo after an intensive Lifestyle Program participants without Type 2 Diabetes who have Obesiy or are Overweight with weight- related Comorbidities: Randomized

	<p>Double Blind, Placebo Controlled Trial. Study coordinator. From April 2021 to present.</p> <p>➤ I8F-MC-GPHD Arandomized, phase 3, open label Trial comparing the effect of the addition of tirzepatide once weekly vs insulin lispro (U100)Three times daily in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin. Study coordinator. From Dec 2020 to present.</p>
--	---

Signature:

Date: